CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $12.81M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
9.49MGBP12.81M · vs all stocks (USD)
Revenue (TTM)
585.61KGBP790.88K · vs all stocks (USD)
Profit Margin
-242.07%vs Biotechnology peers
Beta
2.30xvs all stocks
52-Week Change
168.00%vs all stocks
Market Capitalization
9.49MGBP12.81M · vs all stocks (USD)
Enterprise Value
8.16MGBP11.01M · vs all stocks (USD)
Price to Sales (TTM)
16.20xvs Biotechnology peers
Enterprise to Revenue
13.93xvs Biotechnology peers
Enterprise to EBITDA
-5.76xvs Biotechnology peers
Profit Margin
-242.07%vs Biotechnology peers
Operating Margin
-116.11%vs Biotechnology peers
Return on Assets (TTM)
-211.38%vs Biotechnology peers
Revenue (TTM)
585.61KGBP790.88K · vs all stocks (USD)
Revenue per Share (TTM)
0.0010GBPUpdated Aug 2, 2026Quarterly Revenue Growth
82.70%vs Biotechnology peers
Gross Profit (TTM)
585.61KGBP790.88K · vs all stocks (USD)
EBITDA (TTM)
-1.42MGBP-1.91M · vs all stocks (USD)
Net Income (TTM)
-1.42MGBP-1.91M · vs all stocks (USD)
Operating Cash Flow (TTM)
-1.44MGBP-1.94M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-905.00KGBP-1.22M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 2, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00GBPFY2024 · Dec 31, 2024Operating Income
-1.59MGBP-2.14M · vs all stocks (USD)
Pre-tax Income
-1.59MGBPFY2024 · Dec 31, 2024Income Tax Expense
0.00GBPFY2024 · Dec 31, 2024Net Income
-1.59MGBPFY2024 · Dec 31, 2024EBIT
-1.59MGBPFY2024 · Dec 31, 2024EBITDA (Income Statement)
-1.59MGBPFY2024 · Dec 31, 2024Research & Development
1.15MGBPFY2024 · Dec 31, 2024Selling, General & Administrative
408.29KGBPFY2024 · Dec 31, 2024Non-operating Interest Expense
0.00GBPFY2024 · Dec 31, 2024EPS (Basic)
-0.0047GBPFY2024 · Dec 31, 2024EPS (Diluted)
-0.0047GBPFY2024 · Dec 31, 2024Basic Shares Outstanding
334.46MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
334.46MSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
-1.59MGBPFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Dec 31, 2024Operating Cash Flow
-1.32MGBPFY2024 · Dec 31, 2024Free Cash Flow
-1.32MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
278.68KGBPFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-1.59MGBPFY2024 · Dec 31, 2024Stock-based Compensation
0.00GBPFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
264.52KGBPFY2024 · Dec 31, 2024Capital Expenditures
0.00GBPFY2024 · Dec 31, 2024Net Investing Cash Flow
0.00GBPFY2024 · Dec 31, 2024Net Financing Cash Flow
656.63KGBPFY2024 · Dec 31, 2024Shares Outstanding
493.55MSharesUpdated Aug 2, 2026Float Shares
283.53MSharesUpdated Aug 2, 2026% Held by Insiders
48.85%vs all stocks
% Held by Institutions
2.76%vs all stocks
Total Cash (MRQ)
111.79KGBP150.98K · vs all stocks (USD)
Total Cash per Share (MRQ)
0.00GBPUpdated Aug 2, 2026Total Debt (MRQ)
0.00GBPvs all stocks (USD)
Current Ratio (MRQ)
0.4500xvs Biotechnology peers
Book Value per Share (MRQ)
-0.0010GBPUpdated Aug 2, 2026Total Assets
385.91KGBP521.18K · vs all stocks (USD)
Total Current Assets
383.84KGBPFY2024 · Dec 31, 2024Total Liabilities
788.92KGBPFY2024 · Dec 31, 2024Total Non-current Assets
2.07KGBPFY2024 · Dec 31, 2024Total Non-current Liabilities
0.00GBPFY2024 · Dec 31, 2024Total Current Liabilities
788.92KGBPFY2024 · Dec 31, 2024Cash
278.68KGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents
278.68KGBPFY2024 · Dec 31, 2024Accounts Payable
368.90KGBPFY2024 · Dec 31, 2024Common Stock (Book)
104.91KGBPFY2024 · Dec 31, 2024Retained Earnings
-5.59MGBPFY2024 · Dec 31, 2024Total Shareholders' Equity
-403.01KGBP-544.27K · vs all stocks (USD)
52-Week Low
0.5500GBXUpdated Aug 2, 202652-Week High
3.12GBXUpdated Aug 2, 202652-Week Change
168.00%vs all stocks
Beta
2.30xvs all stocks
50-Day MA
2.03GBXUpdated Aug 2, 2026200-Day MA
2.01GBXUpdated Aug 2, 2026Avg 10-Day Volume
1.51MSharesUpdated Aug 2, 2026Avg 30-Day Volume
1.35MSharesUpdated Aug 2, 2026Diluted EPS (TTM)
-0.0033GBPUpdated Aug 2, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $12.81M, lower than 95% of all stocks globallySignificant
Market cap (USD): 12,812,969.487Global P5: 269,387,740.27
Revenue is $790,880, lower than 95% of all stocks globallySignificant
Revenue (USD): 790,879.822Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
BioLineRx Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cindrigo Holdings Limited
Tier 1ProductionApproval-Gated PipelineFlowRisk
Rua Life Sciences Plc
Tier 1ProductionApproval-Gated PipelineRule
Aptamer Group Plc
Tier 1ProductionApproval-Gated PipelineRule
Inspiration Healthcare Group plc
Tier 1ProductionApproval-Gated PipelineRule
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow